Elicio Therapeutics (ELTX) Price & Analysis

Compare

211 Followers

ELTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.05 - $12.62

Previous CloseN/A

Volume37.28K

Average Volume (3M)88.14K

Market Cap

$176.78M

Enterprise Value$116.79M

Total Cash (Recent Filing)$22.09M

Total Debt (Recent Filing)$14.90M

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Nov 06, 2025

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.66

Shares Outstanding16,338,284

10 Day Avg. Volume60,139

30 Day Avg. Volume88,140

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue100.17

Enterprise Value/Gross Profit-439.07

Enterprise Value/Ebitda-2.22

Forecast

1Y Price Target

$15.50

Price Target Upside43.25% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsElicio's Phase 2 trial showed a rapid pace of enrollment with 135 patients enrolled, which is promising for future trial success.

Drug EfficacyThe IDMC's positive recommendation for the ELI-002 7P trial indicates the study passed its futility hurdle, suggesting promising drug efficacy.

Market ValuationWith positive Phase 2 data, Elicio's platform could obtain a valuation of approximately $100 million, indicating strong market potential.

Bears Say

Cash PositionElicio has approximately $22.1 million in cash and equivalents, which could raise concerns about long-term financial sustainability.

Investor ExpectationsThe stock slightly pulled back as some investors expected an early stoppage of the trial, highlighting investor concerns.

Elicio Therapeutics News

Elicio Therapeutics announces investigator-initiated Phase 1 trial of ELI-002 7P

Elicio Therapeutics (ELTX) announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P in...

9d ago

ELTX

Elicio Therapeutics reports inducement grants

Elicio Therapeutics (ELTX) announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options...

20d ago

ELTX

Elicio reports ELI-002 7P induced T cell responses in 99% of patients

Elicio Therapeutics (ELTX) announced immunogenicity testing data showing that approximately 99% of evaluable patients enrolled in its ongoing...

21d ago

ELTX

Elicio Therapeutics Announces Promising Phase 2 Vaccine Results

An announcement from Elicio Therapeutics ( ($ELTX) ) is now available. On September 17, 2025, Elicio Therapeutics announced...

21d ago

ELTX

Elicio Therapeutics Publishes Promising Phase 1 Study Data

Elicio Therapeutics ( ($ELTX) ) just unveiled an announcement. On August 12, 2025, Elicio Therapeutics announced the publication...

2M ago

ELTX

Elicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 data

Elicio Therapeutics (ELTX) announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in...

2M ago

ELTX

Elicio Therapeutics Reports Q2 2025 Financial Results

Elicio Therapeutics, Inc ( ($ELTX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ELTX

Elicio Therapeutics Advances Phase 2 AMPLIFY-7P Study

The latest announcement is out from Elicio Therapeutics ( ($ELTX) ). On August 5, 2025, Elicio Therapeutics announced...

2M ago

ELTX

Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2

Elicio Therapeutics (ELTX) announced that following the Independent Data Monitoring Committee’s, IDMC, pre-specified interim review of the unblinded...

2M ago

ELTX

Elicio Therapeutics: Promising Trial Results and Commercial Potential Drive Buy Rating

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Elicio Therapeutics today and set a price target...

3M ago

ELTX

Elicio Therapeutics price target raised to $13 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Elicio Therapeutics (ELTX) to $13 from $10 and keeps a...

3M ago

ELTX

Elicio Therapeutics to host virtual KOL event on AMP-powered ELI-002

Elicio Therapeutics (ELTX) will host a virtual key opinion leader event on Wednesday, June 25, 2025 at 2:00...

4M ago

ELTX

Elicio Therapeutics Secures $10M Financing for Operations

An update from Elicio Therapeutics ( ($ELTX) ) is now available. On June 3, 2025, Elicio Therapeutics entered...

4M ago

ELTX

Elicio Therapeutics secures $10M in financing

Elicio Therapeutic has entered a $10M senior secured promissory note with existing investor, GKCC. The proceeds from the...

4M ago

ELTX

ELTX FAQ

What was Elicio Therapeutics’s price range in the past 12 months?

Elicio Therapeutics lowest stock price was $4.05 and its highest was $12.62 in the past 12 months.

What is Elicio Therapeutics’s market cap?

Elicio Therapeutics’s market cap is $176.78M.

When is Elicio Therapeutics’s upcoming earnings report date?

Elicio Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 29 days.

How were Elicio Therapeutics’s earnings last quarter?

Elicio Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.685 by $0.025.

Is Elicio Therapeutics overvalued?

According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Elicio Therapeutics pay dividends?

Elicio Therapeutics does not currently pay dividends.

What is Elicio Therapeutics’s EPS estimate?

Elicio Therapeutics’s EPS estimate is -0.55.

How many shares outstanding does Elicio Therapeutics have?

Elicio Therapeutics has 16,338,284 shares outstanding.

What happened to Elicio Therapeutics’s price movement after its last earnings report?

Elicio Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.685. Following the earnings report the stock price went up 1.433%.

Which hedge fund is a major shareholder of Elicio Therapeutics?

Currently, no hedge funds are holding shares in ELTX

Elicio Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-9999.00%

Trailing 12-Months

Asset Growth

87.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Elicio Therapeutics

Elicio Therapeutics (ELTX) is a biotechnology company focused on developing innovative immunotherapies to treat cancer and other diseases. The company operates in the biopharmaceutical sector and is dedicated to leveraging its proprietary Amphiphile platform to enhance the potency and durability of immune responses. Elicio's core products include a pipeline of cancer vaccines and immune-modulating therapies designed to target and eliminate cancer cells effectively.

Elicio Therapeutics (ELTX) Earnings & Revenues

Historic Earnings Reports

ELTX Stock 12 Month Forecast

Average Price Target

$15.50

▲(43.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","19":"$19"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7,11,15,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.35,10.938461538461539,11.526923076923076,12.115384615384615,12.703846153846154,13.292307692307691,13.88076923076923,14.46923076923077,15.057692307692307,15.646153846153846,16.234615384615385,16.823076923076922,17.411538461538463,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.35,10.746153846153845,11.142307692307693,11.538461538461538,11.934615384615384,12.330769230769231,12.726923076923077,13.123076923076923,13.51923076923077,13.915384615384616,14.311538461538461,14.707692307692309,15.103846153846154,{"y":15.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.35,10.553846153846154,10.757692307692308,10.961538461538462,11.165384615384616,11.36923076923077,11.573076923076922,11.776923076923076,11.98076923076923,12.184615384615384,12.388461538461538,12.592307692307692,12.796153846153846,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.9,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >